Peter K.
FP&A (R&D & Commercial) Pharmaceutical Biopharma Biotech 한국어
- Role
- Director of Financial Planning and Analysis at AVEO Oncology
- Location
- Englewood Cliffs, NJ, US
- LinkedIn followers
- 500 followers
About Peter K.
Financial Analysis & Accounting Leader who delivers results in reporting, budgeting, forecasting & strategic planning for Corporate, Contract Development and Manufacturing Organization, Commercial and R&D functional areas Known for taking ownership of business goals; using collaboration and influence to achieve business’ goals Excellent analytical and investigative skills with value added experience in enhancing Hyperion, ESSBASE reports with broad technical, data management and presentation skills U.S. citizen. Technical & Functional Skills Software: Oracle Hyperion, Oracle BI, ESSBASE, SmartView, SAP, BW, Tableau, SAS, MS Dynamics GP & Management Reporter, Word, Excel, PowerPoint, Access, R&D Logic, Quicken, Valuecentric Valuetrak and Sage 50 Financial, Planning & Analysis: Annual Operations Budget, Monthly & Quarterly forecasts, Profit & Loss Forecast, Statistical Analysis, Excel Modeling / Forecasting: pivots, linking multiple templates, logical and lookup formulas with multiple nesting, Waterfall Charts, Financial Information System Implementation, Cash Flow Forecasting, Accounting: Monthly Closing, Project Accounting, Reporting & Control, Financial Statement Analysis, Capital Expenditure Management Operations: Process Improvement Projects, Project Management, Contract Cost Proposals & Estimates-at-completion, Process Flowcharts, Policy & Procedure documentation and Six Sigma training,
Experience
Director of Financial Planning and Analysis
Feb 2023 — Present · Boston, MA, US
AVEO is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA in immuno-oncology combinations in RCC and other indications, and has several other investigational programs in clinical development. AVEO is committed to creating an environment of diversity, equity and inclusion to diversify representation within the Company.
Education
Saint Peter's University
MBA & BS, Accountancy
2008 — 2010
Binghamton University
Bachelor of Arts, Economics and Political Science
1992 — 1996
Find verified contacts for anyone on LinkedIn
Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.
Free plan included · No credit card required
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.